DexCom Financial Performance

DexCom, Inc. has reported impressive first-quarter revenues of $1.19 billion for 2026, a 15% year-over-year increase that outpaces market expectations. The company's earnings per share rose to 56 cents, surpassing estimates, indicating a positive trajectory despite a recent decline in stock value. Previous weeks highlighted a 20.74% drop in stock prices leading up to this report, alongside strategic initiatives like the FDA approval of its over-the-counter continuous glucose monitoring device, Stelo. These developments position DexCom to strengthen its market share amidst competition, particularly in the growing continuous glucose monitoring sector.